213 related articles for article (PubMed ID: 33737305)
21. INTRAOCULAR DEXAMETHASONE IMPLANT POSITION IN SITU AND OCULAR HYPERTENSION.
Sudhalkar A; Kodjikian L; Chhablani J; Bhojwani D; Vasavada A
Retina; 2018 Dec; 38(12):2343-2349. PubMed ID: 29016454
[TBL] [Abstract][Full Text] [Related]
22. OBSERVED COMPLICATIONS FROM DEXAMETHASONE INTRAVITREAL IMPLANT FOR THE TREATMENT OF MACULAR EDEMA IN RETINAL VEIN OCCLUSION OVER 3 TREATMENT ROUNDS.
Reid GA; Sahota DS; Sarhan M
Retina; 2015 Aug; 35(8):1647-55. PubMed ID: 25932545
[TBL] [Abstract][Full Text] [Related]
23. Association of trabecular meshwork height with steroid-induced ocular hypertension.
Cho WJ; Kim Y; Kim JD; Kim EW; Bae HW; Kim CY; Choi W
Sci Rep; 2023 Jun; 13(1):9143. PubMed ID: 37277443
[TBL] [Abstract][Full Text] [Related]
24. Ocular hypertension management in long-term treatments with intravitreal dexamethasone implants: a 3-year experience.
Monsellato R; Trovato E; Turchetti P; Forestiere M; Pistone A; De Sio S; Accetta L; Pacella F
Clin Ter; 2020; 170(1):e11-e14. PubMed ID: 31850478
[TBL] [Abstract][Full Text] [Related]
25. INTRAOCULAR PRESSURE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 3-YEAR MEAD STUDY.
Maturi RK; Pollack A; Uy HS; Varano M; Gomes AM; Li XY; Cui H; Lou J; Hashad Y; Whitcup SM;
Retina; 2016 Jun; 36(6):1143-52. PubMed ID: 26871523
[TBL] [Abstract][Full Text] [Related]
26. SAFETY OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX): The SAFODEX study. Incidence and Risk Factors of Ocular Hypertension.
Malclès A; Dot C; Voirin N; Vié AL; Agard É; Bellocq D; Denis P; Kodjikian L
Retina; 2017 Jul; 37(7):1352-1359. PubMed ID: 27768641
[TBL] [Abstract][Full Text] [Related]
27. Effect of intravitreal injection of dexamethasone 0.7 mg (Ozurdex®) on intraocular pressure in patients with macular edema.
Mazzarella S; Mateo C; Freixes S; Burés-Jelstrup A; Rios J; Navarro R; García-Arumí J; Corcóstegui B; Arrondo E
Ophthalmic Res; 2015; 54(3):143-9. PubMed ID: 26394206
[TBL] [Abstract][Full Text] [Related]
28. Risk factors for ocular hypertension after intravitreal dexamethasone implantation in diabetic macular edema.
Choi MY; Kwon JW
Sci Rep; 2020 Aug; 10(1):13736. PubMed ID: 32792579
[TBL] [Abstract][Full Text] [Related]
29. TOLERANCE OF INTRAVITREAL DEXAMETHASONE IMPLANTS IN PATIENTS WITH OCULAR HYPERTENSION OR OPEN-ANGLE GLAUCOMA.
Vié AL; Kodjikian L; Malclès A; Agard E; Voirin N; El Chehab H; Nguyen AM; Dot C
Retina; 2017 Jan; 37(1):173-178. PubMed ID: 27465569
[TBL] [Abstract][Full Text] [Related]
30. Phaco-non-penetrating deep sclerectomy in ocular hypertension secondary to dexamethasone intravitreal implant.
Pérez-Sarriegui A; Casas-Llera P; Díez-Álvarez L; Contreras I; Moreno-López M; Figueroa MS; González-Martín-Moro J; Muñoz-Negrete FJ; Rebolleda G
Arch Soc Esp Oftalmol (Engl Ed); 2018 Dec; 93(12):580-585. PubMed ID: 30266279
[TBL] [Abstract][Full Text] [Related]
31. INTRAOCULAR PRESSURE CHANGES AFTER DEXAMETHASONE IMPLANT IN PATIENTS WITH GLAUCOMA AND STEROID RESPONDERS.
Srinivasan R; Sharma U; George R; Raman R; Sharma T;
Retina; 2019 Jan; 39(1):157-162. PubMed ID: 29095355
[TBL] [Abstract][Full Text] [Related]
32. Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis.
Pelegrín L; de la Maza MS; Molins B; Ríos J; Adán A
Eye (Lond); 2015 Jul; 29(7):943-50. PubMed ID: 25998942
[TBL] [Abstract][Full Text] [Related]
33. Safety of 6000 intravitreal dexamethasone implants.
Rajesh B; Zarranz-Ventura J; Fung AT; Busch C; Sahoo NK; Rodriguez-Valdes PJ; Sarao V; Mishra SK; Saatci AO; Udaondo Mirete P; Querques G; Farah ME; Lanzetta P; Arevalo JF; Kodjikian L; Chhablani J;
Br J Ophthalmol; 2020 Jan; 104(1):39-46. PubMed ID: 31040132
[TBL] [Abstract][Full Text] [Related]
34. Secondary glaucoma after intravitreal dexamethasone implant (Ozurdex) injection in patients with retinal disorder: A retrospective study.
Sweta VD; Shibi Dev BN; Sandhya R
Indian J Ophthalmol; 2022 Feb; 70(2):585-589. PubMed ID: 35086242
[TBL] [Abstract][Full Text] [Related]
35. Identification of proteomic changes for dexamethasone-induced ocular hypertension using a tandem mass tag (TMT) approach.
Liang X; Li N; Rong Y; Wang J; Zhang H
Exp Eye Res; 2022 Mar; 216():108914. PubMed ID: 34979099
[TBL] [Abstract][Full Text] [Related]
36. Two or more dexamethasone intravitreal implants in treatment-naïve patients with macular edema due to retinal vein occlusion: subgroup analysis of a retrospective chart review study.
Dugel PU; Capone A; Singer MA; Dreyer RF; Dodwell DG; Roth DB; Shi R; Walt JG; Scott LC; Hollander DA;
BMC Ophthalmol; 2015 Sep; 15():118. PubMed ID: 26337664
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcomes after intravitreal dexamethasone treatment in steroid responders.
Al-Khersan H; Hariprasad SM; Singh SR; Chhablani J;
Acta Diabetol; 2019 Jun; 56(6):675-680. PubMed ID: 30799524
[TBL] [Abstract][Full Text] [Related]
38. [Intraocular pressure elevation and intravitreal steroid implant injection: State of the art in 2023. Recommendations of the French Glaucoma Society and French Ophthalmology Society [French version]].
Dot C; Poli M; Aptel F; Labbe A; Kodjikian L; Baillif S; Bodaghi B; Denis P
J Fr Ophtalmol; 2023 Sep; 46(7):803-810. PubMed ID: 37481449
[TBL] [Abstract][Full Text] [Related]
39. Secondary glaucoma after intravitreal dexamethasone 0.7 mg implant in patients with retinal vein occlusion: a one-year follow-up.
Meyer LM; Schönfeld CL
J Ocul Pharmacol Ther; 2013; 29(6):560-5. PubMed ID: 23480270
[TBL] [Abstract][Full Text] [Related]
40. Intravitreal Dexamethasone Implant in the Treatment of Non-infectious Uveitis.
Hasanreisoğlu M; Özdemir HB; Özkan K; Yüksel M; Aktaş Z; Atalay HT; Özdek Ş; Gürelik G
Turk J Ophthalmol; 2019 Oct; 49(5):250-257. PubMed ID: 31650791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
